Synthesis of new active nitrogen and sulfur containing norlabdanic compounds
Închide
Articolul precedent
Articolul urmator
184 2
Ultima descărcare din IBN:
2020-10-07 11:48
SM ISO690:2012
LUNGU, Lidia; BLAJA, Svetlana; CIOCARLAN, Alexandru; ILKER, Ozer; ARICU, Aculina; VORNICU, Nicoleta. Synthesis of new active nitrogen and sulfur containing norlabdanic compounds. In: Achievements and perspectives of modern chemistry. 9-11 octombrie 2019, Chişinău. Chisinau, Republic of Moldova: Tipografia Academiei de Ştiinţe a Moldovei, 2019, p. 226. ISBN 978-9975-62-428-2.
EXPORT metadate:
Google Scholar
Crossref
CERIF
BibTeX
DataCite
Dublin Core
Achievements and perspectives of modern chemistry 2019
Conferința "International Conference "Achievements and perspectives of modern chemistry""
Chişinău, Moldova, 9-11 octombrie 2019

Synthesis of new active nitrogen and sulfur containing norlabdanic compounds


Pag. 226-226

Lungu Lidia1, Blaja Svetlana1, Ciocarlan Alexandru1, Ilker Ozer1, Aricu Aculina1, Vornicu Nicoleta2
 
1 Institute of Chemistry,
2 Metropolitan Center of Research TABOR, The Metropolitanate of Moldavia and Bukovina
 
Disponibil în IBN: 11 noiembrie 2019


Rezumat

The synthesis of hybrid terpeno-heterocyclic compounds is a recent concern of researchers in the field of natural products. Several papers describing the synthesis and biological activity of terpenic compounds bearing diazine [1,2], carbazole [2], triazole [2,3], oxadiazoleand thiadiazole [4] units have been recently published. It should be noted that the intermediates of terpenoheterocyclic compounds often exhibit biological activity. This communication confirms this fact and presents last-minute results. We report the synthesis of new di- and trinorlabdane thiosemicarbazides 1 and 2, tetranorlabdane 2-iminothiodiazole 3 and diacyl hydrazide 4, obtained in 60%-82% yields Figure 1. The structures of compounds 1-4 were fully confirmed by 1H, 13C and 2D NMR analysis.formulaFigure. New nitrogen and sulfur containing bioactive norlabdanes. Compounds 1-4 were tested in vitro for antifungal and antibacterial activity on five strains of fungi and both Gram-negative and Gram-pozitive bacteria (Table 1). Compound 3 have shown the best antifungal and antibacterial activity at (MIC) of 0.125 μg/mL and 2.5 μg/mL, respectively. Compounds 1, 2 and 4 possess activity comparable with reference compounds Caspofungin and Kanamycin (4 μg/mL). Table. Results of in vitro testing of antibacterial and antifungal activity of compounds 1-4.tabel

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-87374</cfResPublId>
<cfResPublDate>2019</cfResPublDate>
<cfStartPage>226</cfStartPage>
<cfISBN>978-9975-62-428-2</cfISBN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/87374</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'><p>Synthesis of new active nitrogen and sulfur containing norlabdanic compounds</p></cfTitle>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>The synthesis of hybrid terpeno-heterocyclic compounds is a recent concern of researchers in the field of natural products. Several papers describing the synthesis and biological activity of terpenic compounds bearing diazine [1,2], carbazole [2], triazole [2,3], oxadiazoleand thiadiazole [4] units have been recently published. It should be noted that the intermediates of terpenoheterocyclic compounds often exhibit biological activity. This communication confirms this fact and presents last-minute results. We report the synthesis of new di- and trinorlabdane thiosemicarbazides 1 and 2, tetranorlabdane 2-iminothiodiazole 3 and diacyl hydrazide 4, obtained in 60%-82% yields Figure 1. The structures of compounds 1-4 were fully confirmed by 1H, 13C and 2D NMR analysis.</p><p>formula</p><p>Figure. New nitrogen and sulfur containing bioactive norlabdanes. Compounds 1-4 were tested in vitro for antifungal and antibacterial activity on five strains of fungi and both Gram-negative and Gram-pozitive bacteria (Table 1). Compound 3 have shown the best antifungal and antibacterial activity at (MIC) of 0.125 &mu;g/mL and 2.5 &mu;g/mL, respectively. Compounds 1, 2 and 4 possess activity comparable with reference compounds Caspofungin and Kanamycin (4 &mu;g/mL). Table. Results of in vitro testing of antibacterial and antifungal activity of compounds 1-4.</p><p>tabel</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-23821</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-52201</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-12404</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-58399</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11130</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-49779</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-23821</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-23821-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Lungu</cfFamilyNames>
<cfFirstNames>Lidia</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-52201</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-52201-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Blaja</cfFamilyNames>
<cfFirstNames>Svetlana</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-12404</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-12404-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Ciocarlan</cfFamilyNames>
<cfFirstNames>Alexandru</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-58399</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-58399-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Ilker</cfFamilyNames>
<cfFirstNames>Ozer</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11130</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11130-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Aricu</cfFamilyNames>
<cfFirstNames>Aculina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-49779</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-49779-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Vornicu</cfFamilyNames>
<cfFirstNames>Nicoleta</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>